Transcript Atlantic Canada’s Value Proposition

Atlantic Canada’s
Value Proposition
Re$earch Money Conference
November, 2007
Halifax, Nova Scotia
Atlantic Canada’s Value Proposition

Context to remarks
•
•
•
•
Understanding BioVectra Inc. and Diagnostic Chemicals
Limited
Our in-house research capabilities and focus
Our collaborations with Atlantic Canada researchers and
organizations
Our collaborations with Pharmaceutical and Diagnostic
companies
DCL
and
BioVectra
• Founded in 1970 by Dr. Regis Duffy
• Privately held and controlled
• DCL employs over 240 people in 3 countries
• Four manufacturing facilities plus administration
headquarters in Canada; sales and distribution
offices in the United States and Mexico
• Develops, manufactures and markets products
worldwide
DCL and BioVectra
Prince Edward Island, Canada
• Manufacturing / Packaging
• Administration
• Research and Development
• Quality Control
• Regulatory Affairs
• Technical Services
Oxford, Connecticut
• Customer Services and Warehousing
• Field Sales and Technical Services
Mexico City, Mexico
• Customer Services and Warehousing
• Sales and Field Technical Services
Corporate Overview
Revenue 2003-2007
40,000
35,000
30,000
25,000
20,000
Revenue
15,000
10,000
5,000
0
2003
2004
2005
2006
2007
DCL and BioVectra
Actual and Projected Revenue
60000
50000
40000
30000
Revenue
20000
10000
0
2003
2004
2005
2006
2007
2008
2009
Diagnostics
Develops, manufactures and markets worldwide:
•
Chemistry reagents for human and veterinary diagnostics
•
Specialty / Niche chemistry reagents for human and veterinary diagnostics
•
Immunochromatographic point-of-care assays
•
Laboratory consumable manufacturing on a contract basis
Provides services in:
•
Contract Sales and Distribution
•
Custom product formulations/manufacturing
•
Lyophilization, dry and liquid blending
•
Full kitting including dispensing and labeling
•
Applications development / FDA filing
Diagnostics Strategy
R & D:
External Collaboration

•
•
•
Diagnostic companies with problem chemistries
Universities with technologies in clinical
chemistry
Small firms or individuals with unique chemistries
Internal Activities

•
focus on product development
Diagnostics
– keys to success




Focus on Manufacturing Excellence
Unique Products
Customer Service
Human capital
A very good fit with Genzyme Corporation
•
•
•
•
•
•
BioVectra is a cGMP manufacturer of
APIs and advanced intermediates
Fermentation
Bioextractions and purifications
PEG reagents & PEGylation services
Specialty biochemicals and enzymes
Creating partnerships with others
utilizing our applied technologies to
improve or enhance new and existing
products
BioVectra
R & D:
 External collaboration
•
•
•
•
Pharma and Biotech
companies with unique
problems
Universities
NRC-INH
Drug discovery companies
BioVectra
R & D:
 Internal Activities
•
•
•
PEGs ( a product used as part of the
drug, to extend stability and improve
performance )
Taxanes – to gain an advantage in
generic introduction of a semi-synthetic
version of a major oncology drug
New Drug Development program – a
structure to invest in development of
selected candidates
BioVectra
Keys to Success:
•
•
•
•
Focus on Manufacturing
Excellence
Unique Products
Customer Service
Human Capital
Atlantic Canada’s Value Proposition






North American strategic location
Good cost base for technical
activities and manufacturing
Quality of life for employees is
appreciated and creates loyalty
Low bureaucracy, ‘can-do’
attitude
Excellent public support climate
Institutional support - NRC, AVC,
Universities
Atlantic Canada Value Proposition

Strong support and collaborative
system in place; example - PEI
BioAlliance

Canadian Business 2007 ranked
Charlottetown as the 2nd best place to
do business in Canada

Provincial Tax Incentives – Corporate
tax, HR Recruitment support

ACOA Atlantic Innovation Fund (AIF)
reduces product development risks
Some challenges




Experience base is limited among available labor
Challenging to retain young mobile talent
Must overcome perceptions of remote location – access
is an issue
Removed from financial sources typically used by
competition
Atlantic Canada’s Value Proposition

Atlantic Canada can contribute
to the national science and
business goals

Think about it;
• Strong university
environment
• Well educated work force
• Strong work ethic
• Entrepreneurial spirit
• Local government willing to
support economic innovation
Atlantic Canada’s Value Proposition
Some comments:





Message to Governments –
“Atlantic Canada is stepping up” as
a serious business contender in
the science area
ACOA- AIF is an important tool for
technology transfer and
commercialization
Maintain and improve competitive
tax incentives for science based
businesses
Develop policies and incentives to
attract world-class researchers and
highly qualified personnel
Invest more in infrastructure and
less on strategic forms
Atlantic Canada’s Value Proposition

This sector is an opportunity for Atlantic Canada to
shine – We are committed to making this happen